What Théralène 4% Treats: Main Uses and Benefits

This medication is used in situations involving certain distressing symptoms. The clinical applications are applied across domains where additional symptomatic support is needed in specific situations involving heightened patient discomfort.

Théralène 4% is relevant for easing symptoms related to inflammatory or irritative states such as severe pruritus (itching) associated with urticaria (hives), and is applied to manage sleep disturbances and provide pre-operative sedation for children.

“This medication is commonly utilized for symptom clusters that create noticeable physiological strain, where short-term supportive assistance is needed.”

It helps address pronounced discomfort and contributes to easing comfort during periods of heightened symptoms. The sedative property is useful in situations where transient insomnia or restlessness may interfere with the initiation of sleep. Furthermore, it plays a role in managing a dry, non-productive cough that is highly irritative, supporting stability during episodes of heightened discomfort.

---

Quick Fact: Relief for Disruptive Symptoms

Symptom Domain	Key Benefit	Typical Context
Severe Pruritus	May help manage the cycle of itching and scratching.	Acute allergic episodes, such as hives.
Sleep-Onset Difficulty	Supports calmness and assists with the initiation of sleep.	Transient insomnia or sleep disturbances in children.
Irritative Cough	Offers symptomatic relief from persistent dry cough.	Night-time symptoms that interfere with rest.

Who can and cannot use Théralène 4%

This medication’s use is strictly defined by regulatory guidelines concerning patient population, age, and pre-existing health conditions. The following classifications are based solely on official regulatory documents:

Eligibility Classification	Status and Population
Absolute Contraindication	Children less than 2 years of age must not use this medication. It is also prohibited for patients with a known hypersensitivity to phenothiazines, and those with hepatic dysfunction (liver impairment) or renal dysfunction (kidney impairment).
Condition-Specific Exclusion	Use is strictly prohibited for individuals with narrow-angle glaucoma, Parkinson’s disease, and urethroprostatic disorders that carry a risk of urinary retention (e.g., prostatic hypertrophy). The drug is also contraindicated in Myasthenia Gravis.
Conditional Use & Caution	Elderly patients require special caution due to increased susceptibility to effects like orthostatic hypotension. Adults and children over 2 years of age are the generally eligible populations.
Reproductive Status	Use during pregnancy is not recommended unless considered essential. Breastfeeding must be suspended during treatment as the drug may pass into breast milk.

These criteria establish the official eligibility profile for Théralène 4% based on regulatory documents.

Théralène (alimemazine) is a phenothiazine derivative whose interaction profile is primarily defined by its effects on the central nervous system (CNS) and its anticholinergic properties.

Combinations to Avoid

• Alcohol: Consumption of alcoholic beverages or medicines containing alcohol is strongly discouraged, as alcohol significantly intensifies the sedative effects of alimemazine, increasing the risk of CNS depression.
• Adrenaline (Epinephrine): Adrenaline must not be used in patients experiencing an overdose of phenothiazines, including alimemazine, due to the risk of exacerbating hypotension (low blood pressure).

Clinically Significant Interactions

Interacting Medicine/Class	Mechanism & Effect	Relevance
CNS Depressants (e.g., Anxiolytics, Hypnotics, Opioids, Barbiturates, other Sedatives, Tricyclic Antidepressants, MAOIs)	Additive CNS depression (drowsiness, respiratory issues)	Use with Caution
Anticholinergic Drugs (e.g., Atropine-like agents, Anti-Parkinson drugs, Antimuscarinics)	Increased risk of anticholinergic side effects (e.g., constipation, urinary retention, heat stroke).	Use with Caution
Antihypertensives (especially alpha-blockers)	Exaggerated hypotensive effect (sudden drop in blood pressure).	Use with Caution
QT Prolonging Agents (e.g., some Antiarrhythmics) or Drugs causing Electrolyte Imbalance	Increased risk of serious ventricular arrhythmias (abnormal heart rhythm). Caution is advised, especially for patients with cardiac disease or hypokalaemia.	Use with Caution
Gastrointestinal Absorbers (e.g., Antacids, Lithium)	May interfere with the gastrointestinal absorption of alimemazine, potentially reducing its efficacy.	Use with Caution
Hypoglycaemic Agents	High doses of alimemazine can reduce the response to these drugs, possibly requiring dose adjustment.	Monitor Closely

Regulatory warnings emphasize that co-administration with other CNS depressants or anticholinergics can lead to enhanced toxicity, and that alimemazine can oppose the therapeutic action of certain drugs like Levodopa and Amphetamine.

H1 Receptor Antagonism (Primary Mechanism)

Théralène 4% acts primarily through its interaction with the H1 histamine receptor. It exhibits a high affinity for the H1 receptor, leading to the competitive antagonism of histamine binding. This blockade prevents the activation of H1 receptors by endogenous histamine, thereby inhibiting the receptor-mediated signaling cascade.

---

Downstream Cellular Cascade

The downstream effect of H1 receptor blockade reduces mast cell degranulation. This action ultimately decreases the magnitude of histamine-mediated cellular responses throughout peripheral and central systems.

---

D2 Receptor Modulation (Secondary Mechanism)

In addition to its primary role, the compound also acts as a D2 receptor antagonist, resulting in the modulation of central nervous system signaling pathways. This dual-mechanism consists of H1 receptor antagonism combined with D2 receptor antagonism.

Official Administration Guidelines for Théralène 4% Solution

Théralène 4% (alimemazine) oral solution must be administered strictly according to official specifications. The treatment course is intended to be as brief as possible, typically lasting 2 to 5 days.

---

Administration and Dosage

Patient Group	Dosing Schedule (Alimemazine Base)	Frequency and Timing
Adults	5 to 20 mg per day. Treatment must start at the lowest effective dose.	One single dose, 15 to 30 minutes before bedtime.
Children (Weighing >20 kg)	0.25 to 0.5 mg/kg of body weight per day, not to exceed 10 mg total per day.	One single dose, 15 to 30 minutes before bedtime.
Elderly	A decreased dosage is mandatory.	One single dose, 15 to 30 minutes before bedtime.

---

Procedural Steps

The medication is for oral use and must be measured using the dosing pipette supplied in the package.

1. Preparation: Place the bottle on a flat surface and insert the dedicated dosing pipette, graduated in milligrams (mg).
2. Measurement: Position the eye level with the desired graduation mark. Pull the piston to draw the oral solution up to the prescribed dosage line.
3. Administration: Swallow the dose in a single administration as directed. Separate the administration of topical gastrointestinal agents, antacids, or adsorbents by at least two hours to avoid reduced absorption of alimemazine.
4. Cleaning: After use, close the bottle, thoroughly rinse the dosing pipette with water, and dry it before storing it with the medication packaging.

Missed Dose

If a dose is forgotten, do not take a double dose to compensate. Continue the treatment as scheduled with the next dose.

Research Evidence / Overview of Studies for Théralène 4%

---

Evidence for Symptomatic Relief of Pruritus (Itching)

Research examining alimemazine for use in physical discomfort like severe itching (pruritus) is largely supported by systematic reviews of the older class of H1-antihistamines and by regulatory documentation based on its well-established use over time. This approach recognizes that the medicine was studied for managing outcomes linked to inflammatory or irritative states, such as acute outbreaks of hives (urticaria), that support its evaluation, as recognized by regulators. The studies explored how symptoms change over time and focused on outcomes related to physical discomfort, such as the reduction in the patient-reported experience of itching.

Scientific summaries report how symptoms evolved in the observed populations, noting patterns associated with the medicine's use in short-term episodes. However, the evidence quality varies across studies, and there are limited recent, high-quality randomized controlled trials (RCTs) focusing solely on alimemazine compared to a non-treatment (placebo).

Evidence for Managing Transient Sleep Disturbances

Research exploring short-term changes in sleep patterns has primarily centered on pediatric populations evaluated for difficulty with sleep onset or frequent night waking (transient insomnia). These studies included short-term Randomized Controlled Trials (RCTs). Researchers examined outcomes such as the time to sleep onset and the duration of continuous sleep, often relying on parental- or patient-reported outcomes describing perceived discomfort related to sleep disturbances.

Findings related to the measurement of sleep parameters were mixed across the available studies, and data show patterns related to short-term changes measured during the defined study periods. The certainty remains low because the evidence quality varies across studies, and sample sizes were modest in many of the trials conducted.

---

What Research Still Shows as Uncertain

Research exploring long-term outcomes for alimemazine is generally limited. Long-term effects are not fully established regarding the durability of any observed response, as the studies conducted primarily involve short-term follow-up durations (typically a few days or weeks). Additionally, comparative evidence is lacking when looking at how this older medicine performs against newer therapeutic options for many of its applications. The main limitations noted in the scientific literature often point to the fact that sample sizes were modest and evidence quality varies across studies.

Key Studies & References

1. WHO Collaborating Centre for Drug Statistics Methodology (ATC/DDD Index): R06AD01 - Alimemazine

How to Store and Dispose of Théralène 4% Solution Buvable

The official regulatory labeling specifies mandatory conditions for storing and disposing of Théralène 4% oral solution (alimemazine tartrate).

---

Storage Requirements

• The solution must be stored at a temperature below 25°C and must be kept protected from light.
• It is mandatory to keep the medicine out of the reach and sight of children.
• The shelf-life is 36 months before the bottle is opened and 7 months after the bottle is first opened, provided the required storage conditions are maintained.

---

Disposal Instructions

• Do not dispose of the solution in household garbage or down the drain/wastewater.
• Any unused or expired product, including the bottle and the dosing pipette, must be returned to a pharmacist for proper destruction in accordance with regulations.